Idelalisib Recruiting Phase 1 / 2 Trials for Recurrences / Metastasis / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs